The American Diabetes Association’s (ADA’s) Standards of Medical Care in Diabetes
is updated and published annually in a supplement to the January issue of Diabetes
Care. The Standards are developed by the ADA’s multidisciplinary Professional Practice
Committee, which comprises physicians, diabetes educators, and other expert diabetes
health care professionals. The Standards include the most current evidence-based recommendations
for diagnosing and treating adults and children with all forms of diabetes. ADA’s
grading system uses A, B, C, or E to show the evidence level that supports each recommendation.
A—Clear evidence from well-conducted, generalizable randomized controlled trials that
are adequately powered
B—Supportive evidence from well-conducted cohort studies
C—Supportive evidence from poorly controlled or uncontrolled studies
E—Expert consensus or clinical experience
This is an abridged version of the current Standards containing the evidence-based
recommendations most pertinent to primary care. The recommendations, tables, and figures
included here retain the same numbering used in the complete 2020 Standards and so
are not numbered sequentially in this abridged version. All of the recommendations
included here are substantively the same as in the complete Standards. The abridged
version does not include references. The complete 2020 Standards of Care, including
all supporting references, is available at professional.diabetes.org/standards.
1. IMPROVING CARE AND PROMOTING HEALTH IN POPULATIONS
Diabetes and Population Health
Population health is defined as “the health outcomes of a group of individuals, including
the distribution of health outcomes within the group”; these outcomes can be measured
in terms of health outcomes (mortality, morbidity, health, and functional status),
disease burden (incidence and prevalence), and behavioral and metabolic factors (exercise,
diet, A1C, etc.).
Recommendations
1.1 Ensure treatment decisions are timely, rely on evidence-based guidelines, and
are made collaboratively with patients based on individual preferences, prognoses,
and comorbidities. B
1.2 Align approaches to diabetes management with the Chronic Care Model (CCM). This
model emphasizes person-centered team care, integrated long-term treatment approaches
to diabetes and comorbidities, and ongoing collaborative communication and goal setting
between all team members. A
1.3 Care systems should facilitate team-based care and utilization of patient registries,
decision support tools, and community involvement to meet patient needs. B
1.4 Assess diabetes health care maintenance using reliable and relevant data metrics
to improve processes of care and health outcomes, with simultaneous emphasis on care
costs. B
Six Core Elements
The CCM includes six core elements to optimize the care of patients with chronic disease:
1. Delivery system design (moving from a reactive to a proactive care delivery system
where planned visits are coordinated through a team-based approach)
2. Self-management support
3. Decision support (basing care on evidence-based, effective care guidelines)
4. Clinical information systems (using registries that can provide patient-specific
and population-based support to the care team)
5. Community resources and policies (identifying or developing resources to support
healthy lifestyles)
6. Health systems (to create a quality-oriented culture)
A 5-year effectiveness study of the CCM in 53,436 primary care patients with type
2 diabetes suggested that the use of this model of care delivery reduced the cumulative
incidence of diabetes-related complications and all-cause mortality. Patients who
were enrolled in the CCM experienced a reduction in cardiovascular disease (CVD) risk
by 56.6%, microvascular complications by 11.9%, and mortality by 66.1%. The same study
suggested that health care utilization was lower in the CCM group, resulting in health
care savings of $7,294 per individual over the study period.
Strategies for System-Level Improvement
1. Care teams
2. Telemedicine
3. Behaviors and well-being
4. Cost considerations
5. Access to care and quality improvement
Tailoring Treatment for Social Context
Recommendations
1.5 Providers should assess social context, including potential food insecurity, housing
stability, and financial barriers, and apply that information to treatment decisions.
A
1.6 Refer patients to local community resources when available. B
1.7 Provide patients with self-management support from lay health coaches, navigators,
or community health workers when available. A
Health inequities related to diabetes and its complications are well documented and
are heavily influenced by social determinants of health (SDoH). SDoH are defined as
the economic, environmental, political, and social conditions in which people live
and are responsible for a major part of health inequality worldwide. The ADA recognizes
the association between social and environmental factors and the prevention and treatment
of diabetes and has issued a call for research that seeks to better understand how
these SDoH influence behaviors and how the relationships between these variables might
be modified for the prevention and management of diabetes.
The complete 2020 Standards of Care include a discussion of assessment and treatment
considerations in the context of food insecurity, homelessness, seasonal agricultural
work, and language barriers.
2. CLASSIFICATION AND DIAGNOSIS OF DIABETES
Classification
Diabetes can be classified into the following general categories:
1. Type 1 diabetes (due to autoimmune β-cell destruction, usually leading to absolute
insulin deficiency)
2. Type 2 diabetes (due to a progressive loss of β-cell insulin secretion frequently
on the background of insulin resistance)
3. Gestational diabetes mellitus (GDM; diabetes diagnosed in the second or third trimester
of pregnancy that was not clearly overt diabetes prior to gestation)
4. Specific types of diabetes due to other causes, e.g., monogenic diabetes syndromes
(such as neonatal diabetes and maturity-onset diabetes of the young), diseases of
the exocrine pancreas (such as cystic fibrosis and pancreatitis), and drug- or chemical-induced
diabetes (such as with glucocorticoid use, in the treatment of HIV/AIDS, or after
organ transplantation)
It is important for providers to realize that classification of diabetes type is not
always straightforward at presentation, and misdiagnosis may occur. The diagnosis
may become more obvious over time and should be reevaluated if there is concern.
Screening and Diagnostic Tests for Prediabetes and Type 2 Diabetes
The diagnostic criteria for diabetes and prediabetes are shown in Table 2.2/2.5.
TABLE 2.2/2.5
Criteria for the screening and diagnosis of prediabetes and diabetes
Prediabetes
Diabetes
A1C
5.7–6.4% (39–47 mmol/mol)*
≥6.5% (48 mmol/mol)†
Fasting plasma glucose
100–125 mg/dL (5.6–6.9 mmol/L)*
≥126 mg/dL (7.0 mmol/L)†
Oral glucose tolerance test
140–199 mg/dL (7.8–11.0 mmol/L)*
≥200 mg/dL (11.1 mmol/L)†
Random plasma glucose
≥200 mg/dL (11.1 mmol/L)‡
Adapted from Tables 2.2 and 2.5 in the complete Standards of Care. *For all three
tests, risk is continuous, extending below the lower limit of the range and becoming
disproportionately greater at the higher end of the range. †In the absence of unequivocal
hyperglycemia, diagnosis requires two abnormal test results from the same sample or
in two separate samples. ‡Only diagnostic in a patient with classic symptoms of hyperglycemia
or hyperglycemic crisis.
Recommendations
2.6 Screening for prediabetes and type 2 diabetes with an informal assessment of risk
factors or validated tools should be considered in asymptomatic adults. B
2.7 Testing for prediabetes and/or type 2 diabetes in asymptomatic people should be
considered in adults of any age with overweight or obesity (BMI ≥25 kg/m2 or ≥23 kg/m2
in Asian Americans) and who have one or more additional risk factors for diabetes
(Table 2.3). B
2.8 Testing for prediabetes and/or type 2 diabetes should be considered in women planning
pregnancy with overweight or obesity and/or who have one or more additional risk factor
for diabetes (Table 2.3). C
2.9 For all people, testing should begin at age 45 years. B
2.10 If tests are normal, repeat testing carried out at a minimum of 3-year intervals
is reasonable. C
2.12 In patients with prediabetes and type 2 diabetes, identify and treat other CVD
risk factors. B
2.13 Risk-based screening for prediabetes and/or type 2 diabetes should be considered
after the onset of puberty or after 10 years of age, whichever occurs earlier, in
children and adolescents with overweight (BMI ≥85th percentile) or obesity (BMI ≥95th
percentile) and who have additional risk factors for diabetes. (See Table 2.4 for
evidence grading of risk factors.)
TABLE 2.3
Criteria for testing for diabetes or prediabetes in asymptomatic adults
1. Testing should be considered in adults with overweight or obesity (BMI ≥25 kg/m2
or ≥23 kg/m2 in Asian Americans) who have one or more of the following risk factors:
• First-degree relative with diabetes
• High-risk race/ethnicity (e.g., African American, Latino, Native American, Asian
American, Pacific Islander)
• History of CVD
• Hypertension (≥140/90 mmHg or on therapy for hypertension)
• HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level >250
mg/dL (2.82 mmol/L)
• Women with polycystic ovary syndrome
• Physical inactivity
• Other clinical conditions associated with insulin resistance (e.g., severe obesity,
acanthosis nigricans)
2. Patients with prediabetes (A1C ≥5.7% [39 mmol/mol], impaired glucose tolerance,
or impaired fasting glucose) should be tested yearly.
3. Women who were diagnosed with GDM should have lifelong testing at least every 3
years.
4. For all other patients, testing should begin at age 45 years.
5. If results are normal, testing should be repeated at a minimum of 3-year intervals,
with consideration of more frequent testing depending on initial results and risk
status.
TABLE 2.4
Risk-based screening for type 2 diabetes or prediabetes in asymptomatic children and
adolescents in a clinical setting
Testing should be considered in youth* with overweight (≥85th percentile) or obesity
(≥95th percentile) A who have one or more additional risk factors based on the strength
of their association with diabetes:
• Maternal history of diabetes or GDM during the child’s gestation A
• Family history of type 2 diabetes in first- or second-degree relative A
• Race/ethnicity (Native American, African American, Latino, Asian American, Pacific
Islander) A
• Signs of insulin resistance or conditions associated with insulin resistance (acanthosis
nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small-for-gestational-age
birth weight) B
*
After the onset of puberty or after 10 years of age, whichever occurs earlier. If
tests are normal, repeat testing at a minimum of 3-year intervals, or more frequently
if BMI is increasing, is recommended. Reports of type 2 diabetes before age 10 years
exist, and this can be considered with numerous risk factors.
Marked discrepancies between measured A1C and plasma glucose levels should prompt
consideration that the A1C assay may not be reliable for that individual, and one
should consider using an assay without interference or plasma blood glucose criteria
for diagnosis. (See “6. Glycemic Targets” in the complete 2020 Standards of Care for
conditions causing discrepancies.) Unless there is a clear clinical diagnosis based
on overt signs of hyperglycemia, diagnosis requires two abnormal test results from
the same sample or in two separate test samples. If using two separate test samples,
it is recommended that the second test, which may either be a repeat of the initial
test or a different test, be performed without delay. If the patient has a test result
near the margins of the diagnostic threshold, the provider should follow the patient
closely and repeat the test in 3–6 months.
3. PREVENTION OR DELAY OF TYPE 2 DIABETES
Recommendation
3.1 At least annual monitoring for the development of type 2 diabetes in those with
prediabetes is suggested. E
Screening for prediabetes and type 2 diabetes risk through an informal assessment
of risk factors (Table 2.3) or with an assessment tool such as the ADA risk test (diabetes.org/socrisktest)
is recommended to guide providers on whether performing a diagnostic test for prediabetes
and previously undiagnosed type 2 diabetes (Table 2.2/2.5) is appropriate. Those who
are determined to be at high risk for type 2 diabetes, including people with an A1C
of 5.7–6.4% (39–47 mmol/mol), impaired glucose tolerance, or impaired fasting glucose,
are ideal candidates for diabetes prevention efforts.
Lifestyle Interventions
Recommendations
3.2 Refer patients with prediabetes to an intensive behavioral lifestyle intervention
program modeled on the Diabetes Prevention Program (DPP) to achieve and maintain 7%
loss of initial body weight and increase moderate-intensity physical activity (such
as brisk walking) to at least 150 min/week. A
3.3 A variety of eating patterns are acceptable for persons with prediabetes. B
3.4 Based on patient preference, technology-assisted diabetes prevention interventions
may be effective in preventing type 2 diabetes and should be considered. B
3.5 Given the cost-effectiveness of diabetes prevention, such intervention programs
should be covered by third-party payers. B
The DPP trial demonstrated that an intensive lifestyle intervention could reduce the
incidence of type 2 diabetes by 58% over 3 years. Follow-up of three large studies
of lifestyle intervention for diabetes prevention has shown sustained reduction in
the rate of conversion to type 2 diabetes: 39% reduction at 30 years in the Da Qing
Diabetes Prevention Study, 43% reduction at 7 years in the Finnish Diabetes Prevention
Study, and 34% reduction at 10 years and 27% reduction at 15 years in the U.S. Diabetes
Prevention Program Outcomes Study.
Pharmacologic Interventions
Recommendation
3.6 Metformin therapy for prevention of type 2 diabetes should be considered in those
with prediabetes, especially for those with BMI ≥35 kg/m2, those aged <60 years, and
women with prior GDM. A
Although no drugs have been approved by the U.S. Food and Drug Administration (FDA)
for diabetes prevention, several have shown promise in research studies. Metformin
has the strongest evidence base and demonstrated long-term safety as pharmacologic
therapy for diabetes prevention. Cost, side effects, and durable efficacy require
consideration when using other pharmacologic agents for diabetes prevention in those
with prediabetes.
Prevention of CVD
Recommendation
3.8 Prediabetes is associated with heightened cardiovascular (CV) risk; therefore,
screening for and treatment of modifiable risk factors for CVD are suggested. B
Diabetes Self-Management Education and Support
Recommendation
3.9 Diabetes self-management education and support (DSMES) programs may be appropriate
venues for people with prediabetes to receive education and support to develop and
maintain behaviors that can prevent or delay the development of type 2 diabetes. B
4. COMPREHENSIVE MEDICAL EVALUATION AND ASSESSMENT OF COMORBIDITIES
Patient-Centered Collaborative Care
Recommendations
4.1 A patient-centered communication style that uses person-centered and strength-based
language and active listening; elicits patient preferences and beliefs; and assesses
literacy, numeracy, and potential barriers to care should be used to optimize patient
health outcomes and health-related quality of life. B
4.2 Diabetes care should be managed by a multidisciplinary team that may draw from
primary care physicians, subspecialty physicians, nurse practitioners, physician assistants,
nurses, dietitians, exercise specialists, pharmacists, dentists, podiatrists, and
mental health professionals. E
Individuals with diabetes must assume an active role in their care. The goals of treatment
for diabetes are to prevent or delay complications and maintain quality of life. Treatment
goals and plans for meeting them should be created collaboratively with patients (Figure
4.1).
FIGURE 4.1
Decision cycle for patient-centered glycemic management in type 2 diabetes. HbA1c,
glycated hemoglobin. Reprinted from Davies MJ, D’Alessio DA, Fradkin J, et al. Diabetes
Care 2018;41:2669–2701.
Comprehensive Medical Evaluation
Recommendations
4.3 A complete medical evaluation should be performed at the initial visit to:
Confirm the diagnosis and classify diabetes. B
Evaluate for diabetes complications and potential comorbid conditions. B
Review previous treatment and risk factor control in patients with established diabetes.
B
Begin patient engagement in the formulation of a care management plan. B
Develop a plan for continuing care. B
4.4 A follow-up visit should include most components of the initial comprehensive
medical evaluation, including interval medical history, assessment of medication-taking
behavior and intolerance/side effects, physical examination, laboratory evaluation
as appropriate to assess attainment of A1C and metabolic targets, and assessment of
risk for complications, diabetes self-management behaviors, nutrition, psychosocial
health, and the need for referrals, immunizations, or other routine health maintenance
screening. B
4.5 Ongoing management should be guided by the assessment of diabetes complications
and shared decision-making to set therapeutic goals. B
4.6 The 10-year risk of a first atherosclerotic cardiovascular disease (ASCVD) event
should be assessed using the race- and sex-specific Pooled Cohort Equations to better
stratify ASCVD risk. B
Immunizations
Children and adults with diabetes should receive vaccinations according to age-specific
recommendations. The Centers for Disease Control and Prevention provides vaccination
schedules at www.cdc.gov/vaccines/schedules.
Assessment of Comorbidities
Besides assessing diabetes-related complications, clinicians and their patients need
to be aware of common comorbidities that may complicate diabetes management.
Autoimmune Diseases
Recommendations
4.12 Patients with type 1 diabetes should be screened for autoimmune thyroid disease
soon after diagnosis and periodically thereafter. B
4.13 Adult patients with type 1 diabetes should be screened for celiac disease in
the presence of gastrointestinal symptoms, signs, or laboratory manifestations suggestive
of celiac disease. B
Cancer
Patients with diabetes should be encouraged to undergo recommended age- and sex-appropriate
cancer screenings and to reduce their modifiable cancer risk factors (obesity, physical
inactivity, and smoking).
Other Conditions
Nonalcoholic fatty liver disease, hepatitis C infection, pancreatitis, hearing impairment,
HIV, cognitive impairment/dementia, hip fractures, low testosterone in men, obstructive
sleep apnea, and periodontal disease are all more common in people with diabetes.
See “4. Comprehensive Medical Evaluation and Assessment of Comorbidities” in the complete
2020 Standards of Care for discussion on these topics.
5. FACILITATING BEHAVIOR CHANGE AND WELL-BEING TO IMPROVE HEALTH OUTCOMES
Effective behavior management and psychological well-being are foundational to achieving
treatment goals for people with diabetes. Essential to achieving these goals are DSMES,
medical nutrition therapy (MNT), routine physical activity, smoking cessation counseling
when needed, and psychosocial care.
DSMES
Recommendations
5.1 In accordance with the national standards for DSMES, all people with diabetes
should participate in diabetes self-management education (DSME) and receive the support
needed to facilitate the knowledge, decision-making, and skills mastery necessary
for diabetes self-care. A
5.2 There are four critical times to evaluate the need for DSME to promote skills
acquisition in support of regimen implementation, MNT, and well-being: at diagnosis,
annually, when complicating factors arise, and when transitions in care occur. E
5.3 Clinical outcomes, health status, and well-being are key goals of DSMES that should
be measured as part of routine care. C
5.4 DSMES should be patient centered, may be given in group or individual settings
and/or use technology, and should be communicated with the entire diabetes care team.
A
Medical Nutrition Therapy
Evidence suggests that there is not an ideal percentage of calories from carbohydrate,
protein, and fat for all people with diabetes. Therefore, macronutrient distribution
should be based on an individualized assessment of current eating patterns, preferences,
and metabolic goals. Consider personal preferences (e.g., tradition, culture, religion,
health beliefs, and economics) as well as metabolic goals when working with individuals
to determine the best eating pattern for them. An individualized eating pattern considers
the individual’s health status, skills, resources, food preferences, and health goals.
Referral to a registered dietitian nutritionist (RD/RDN) is essential to assess the
overall nutrition status of, and to work collaboratively with, the patient to create
a personalized meal plan that coordinates and aligns with the overall treatment plan,
including physical activity and medication use.
Physical Activity
Recommendations
5.24 Children and adolescents with type 1 or type 2 diabetes or prediabetes should
engage in 60 min/day or more of moderate- or vigorous-intensity aerobic activity,
with vigorous muscle-strengthening and bone-strengthening activities at least 3 days/week.
C
5.25 Most adults with type 1 C and type 2 B diabetes should engage in 150 min or more
of moderate- to vigorous-intensity aerobic activity per week, spread over at least
3 days/week, with no more than 2 consecutive days without activity. Shorter durations
(minimum 75 min/week) of vigorous-intensity or interval training may be sufficient
for younger and more physically fit individuals.
5.26 Adults with type 1 C and type 2 B diabetes should engage in 2–3 sessions/week
of resistance exercise on nonconsecutive days.
5.27 All adults, and particularly those with type 2 diabetes, should decrease the
amount of time spent in daily sedentary behavior. B Prolonged sitting should be interrupted
every 30 min for blood glucose benefits. C
5.28 Flexibility training and balance training are recommended 2–3 times/week for
older adults with diabetes. Yoga and tai chi may be included based on individual preferences
to increase flexibility, muscular strength, and balance. C
The ADA position statement “Physical Activity/Exercise and Diabetes” offers specific
recommendations and precautions related to type of diabetes, age, activity done, and
presence of diabetes-related health complications including retinopathy, peripheral
neuropathy, autonomic neuropathy, and diabetic kidney disease (DKD).
Smoking Cessation: Tobacco and E-Cigarettes
Recommendations
5.29 Advise all patients not to use cigarettes and other tobacco products A or e-cigarettes.
A
5.30 After identification of tobacco or e-cigarette use, include smoking cessation
counseling and other forms of treatment as a routine component of diabetes care. A
Psychosocial Issues
Recommendations
5.32 Psychosocial screening and follow-up may include, but are not limited to, attitudes
about diabetes, expectations for medical management and outcomes, affect or mood,
general and diabetes-related quality of life, available resources (financial, social,
and emotional), and psychiatric history. E
5.33 Providers should consider assessment for symptoms of diabetes distress, depression,
anxiety, disordered eating, and cognitive capacities using appropriate standardized
and validated tools at the initial visit, at periodic intervals, and when there is
a change in disease, treatment, or life circumstance. Including caregivers and family
members in this assessment is recommended. B
5.34 Consider screening older adults (aged ≥65 years) with diabetes for cognitive
impairment and depression. B
5.36 Consider screening for anxiety in people exhibiting anxiety or worries regarding
diabetes complications, insulin administration, and taking medications, as well as
fear of hypoglycemia and/or hypoglycemia unawareness that interferes with self-management
behaviors, and in those who express fear, dread, or irrational thoughts and/or show
anxiety symptoms such as avoidance behaviors, excessive repetitive behaviors, or social
withdrawal. Refer for treatment if anxiety is present. B
5.44 Annually screen people who are prescribed atypical antipsychotic medications
for prediabetes or diabetes. B
Diabetes distress refers to significant negative psychological reactions to emotional
burdens and worries specific to an individual’s experience in having to manage a severe,
complicated, and demanding chronic disease such as diabetes. Validated tools are available
to measure the level of distress and identify issues that care team members may address.
The ADA position statement “Psychosocial Care for People With Diabetes” provides a
list of assessment tools and additional details.
6. GLYCEMIC TARGETS
Assessment of Glycemic Control
Glycemic management is primarily assessed with the A1C test, the primary measure studied
in clinical trials demonstrating the benefits of improved glycemic control. Self-monitoring
of blood glucose (SMBG) may help with self-management and medication adjustment, particularly
in individuals taking insulin. Continuous glucose monitoring (CGM) also has an important
role in assessing the effectiveness and safety of treatment in many patients with
type 1 diabetes, and limited data suggest it may also be helpful in selected patients
with type 2 diabetes, such as those on intensive insulin regimens.
A1C Testing
Recommendations
6.1 Perform the A1C test at least two times a year in patients who are meeting treatment
goals (and who have stable glycemic control). E
6.2 Perform the A1C test quarterly in patients whose therapy has changed or who are
not meeting glycemic goals. E
6.3 Point-of-care testing for A1C provides the opportunity for more timely treatment
changes. E
Glucose Assessment
Recommendations
6.4 Standardized, single-page glucose reports with visual cues such as the Ambulatory
Glucose Profile (AGP) should be considered as a standard printout for all CGM devices.
E
6.5 Time in range is associated with the risk of microvascular complications and should
be an acceptable end point for clinical trials and can be used for assessment of glycemic
control. Additionally, time below target (<70 and <54 mg/dL [3.9 and 3.0 mmol/L])
and time above target (>180 mg/dL [10.0 mmol/L]) are useful parameters for reevaluation
of the treatment regimen. E
Glucose monitoring is key for the achievement of glycemic targets for many people
with diabetes. SMBG is an integral component of effective therapy for patients taking
insulin. CGM has emerged as a complementary method for the assessment of glucose levels.
The patient’s specific needs and goals should dictate SMBG frequency and timing or
the consideration of CGM use.
Glucose Assessment Using CGM
CGM has evolved rapidly in both accuracy and affordability. To make CGM metrics more
actionable, standardized reports with visual cues such as the AGP (Figure 6.1) are
recommended and may help patients and providers interpret the data and use it to guide
treatment decisions.
FIGURE 6.1
Sample AGP report. Adapted from Battelino T, Danne T, Bergenstal RM, et al. Diabetes
Care 2019;42:1593–1603.
A1C Goals
Recommendations
6.6 An A1C goal for many nonpregnant adults of <7% (53 mmol/mol) is appropriate. A
6.7 On the basis of provider judgment and patient preference, achievement of lower
A1C levels (such as <6.5%) may be acceptable if this can be achieved safely without
significant hypoglycemia or other adverse effects of treatment. C
6.8 Less stringent A1C goals (such as <8% [64 mmol/mol]) may be appropriate for patients
with a history of severe hypoglycemia, limited life expectancy, advanced microvascular
or macrovascular complications, extensive comorbid conditions, or long-standing diabetes
in whom the goal is difficult to achieve despite DSME, appropriate glucose monitoring,
and effective doses of multiple glucose-lowering agents including insulin. B
6.9 Reassess glycemic targets over time based on the criteria in Figure 6.2. E
FIGURE 6.2
Depicted are patient and disease factors used to determine optimal A1C targets. Characteristics
and predicaments toward the left justify more stringent efforts to lower A1C; those
toward the right suggest less stringent efforts. A1C 7%553 mmol/mol. Adapted with
permission from Inzucchi SE, Bergenstal RM, Buse JB, et al. Diabetes Care 2015;38:140–149.
See “6. Glycemic Targets,”
“13. Children and Adolescents,” and “14. Management of Diabetes in Pregnancy” in the
complete 2020 Standards of Care. Table 6.3 summarizes glycemic recommendations for
many nonpregnant adults.
TABLE 6.3
Summary of glycemic recommendations for many nonpregnant adults with diabetes
A1C
<7.0% (53 mmol/mol)*
Preprandial capillary plasma glucose
80–130 mg/dL* (4.4–7.2 mmol/L)
Peak postprandial capillary plasma glucose†
<180 mg/dL* (10.0 mmol/L)
*
More or less stringent glycemic goals may be appropriate for individual patients.
Goals should be individualized based on duration of diabetes, age/life expectancy,
comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia
unawareness, and individual patient considerations. †Postprandial glucose may be targeted
if A1C goals are not met despite reaching preprandial glucose goals. Postprandial
glucose measurements should be made 1–2 h after the beginning of the meal, generally
peak levels in patients with diabetes.
Hypoglycemia
Table 6.4 summarizes the classification of hypoglycemia levels.
TABLE 6.4
Classification of hypoglycemia
Glycemic criteria/description
Level 1
Glucose <70 mg/dL (3.9 mmol/L) and ≥54 mg/dL (3.0 mmol/L)
Level 2
Glucose <54 mg/dL (3.0 mmol/L)
Level 3
A severe event characterized by altered mental and/or physical status requiring assistance
for treatment of hypoglycemia
Reprinted from Agiostratidou G, Anhalt H, Ball D, et al. Diabetes Care 2017;40:1622–1630.
Recommendations
6.10 Individuals at risk for hypoglycemia should be asked about symptomatic and asymptomatic
hypoglycemia at each encounter. C
6.11 In patients taking medication that can lead to hypoglycemia, investigate, screen,
and assess risk for or occurrence of unrecognized hypoglycemia, considering that patients
may have hypoglycemia unawareness. C
6.12 Glucose (15–20 g) is the preferred treatment for the conscious individual with
blood glucose <70 mg/dL [3.9 mmol/L]), although any form of carbohydrate that contains
glucose may be used. Fifteen minutes after treatment, if SMBG shows continued hypoglycemia,
the treatment should be repeated. Once SMBG returns to normal, the individual should
consume a meal or snack to prevent recurrence of hypoglycemia. B
6.13 Glucagon should be prescribed for all individuals at increased risk of level
2 hypoglycemia, defined as blood glucose <54 mg/dL (3.0 mmol/L), so it is available
should it be needed. Caregivers, school personnel, or family members of these individuals
should know where it is and when and how to administer it. Glucagon administration
is not limited to health care professionals, particularly with the availability of
intranasal and stable soluble glucagon available in autoinjector pens. E
6.14 Hypoglycemia unawareness or one or more episodes of level 3 hypoglycemia should
trigger hypoglycemia avoidance education and reevaluation of the treatment regimen.
E
6.15 Insulin-treated patients with hypoglycemia unawareness, one level 3 hypoglycemic
event, or a pattern of unexplained level 2 hypoglycemia should be advised to raise
their glycemic targets to strictly avoid hypoglycemia for at least several weeks in
order to partially reverse hypoglycemia unawareness and reduce risk of future episodes.
A
6.16 Ongoing assessment of cognitive function is suggested with increased vigilance
for hypoglycemia by the clinician, patient, and caregivers if low cognition or declining
cognition is found. B
7. DIABETES TECHNOLOGY
Diabetes technology describes the devices, software, and hardware used to manage diabetes.
It includes delivery systems such as insulin pumps, pens, and syringes as well as
CGM devices and glucose meters. Newer forms of diabetes technology include hybrid
devices that both deliver insulin and monitor glucose levels and software that provides
diabetes self-management support. Increased patient interest has increased the use
of diabetes technology in the primary care setting.
Recommendation
7.1 Use of technology should be individualized based on a patient’s needs, desires,
skill level, and availability of devices. Nonprofit websites can offer advice for
providers and patients to determine the suitability of various options. E
SMBG
Recommendations
7.2 Most patients using intensive insulin regimens (multiple daily injection [MDI]
or continuous subcutaneous insulin infusion [CSII; insulin pump therapy]) should be
encouraged to assess glucose levels using SMBG (and/or CGM) prior to meals and snacks,
at bedtime, prior to exercise, when they suspect low blood glucose, after treating
low blood glucose until they are normoglycemic, and prior to and while performing
critical tasks such as driving. B
7.3 When prescribed as part of a DSMES program, SMBG may help to guide treatment decisions
and/or self-management for patients taking less frequent insulin injections. B
CGM
Table 7.3 defines the types of available CGM devices.
Recommendations
7.11 When used properly, real-time and intermittently scanned CGM in conjunction with
insulin therapy are useful tools to lower A1C and/or reduce hypoglycemia in adults
with type 2 diabetes who are not meeting glycemic targets. B
The use of real-time CGM in adults with type 1 diabetes on either CSII or MDI is supported
by data showing reduction in both hypoglycemia and A1C. People with type 2 diabetes
on CSII or MDI have shown significant reduction in A1C in multiple studies of real-time
or intermittently scanned CGM but did not show a reduction in hypoglycemia.
TABLE 7.3
CGM devices
Real-time CGM
CGM systems that measure glucose levels continuously and provide the user automated
alarms and alerts at specific glucose levels and/or for changing glucose levels.
Intermittently scanned CGM
CGM systems that measure glucose levels continuously but only display glucose values
when swiped by a reader or a smart phone that reveals the glucose levels.
Blinded (professional) CGM
CGM devices that measure glucose levels that are not displayed to the patient in real
time. These devices are generally initiated in a clinic, using a reader that is owned
by the clinic. They are removed after a period of time (generally 10–14 days) and
analyzed by the patient and provider to assess glycemic patterns and trends.
Unblinded CGM
CGM devices that measure glucose levels that are displayed to the patient.
8. OBESITY MANAGEMENT FOR THE TREATMENT OF TYPE 2 DIABETES
There is strong evidence that treating obesity can delay the progression from prediabetes
to type 2 diabetes. It also has been shown to be beneficial in the treatment of type
2 diabetes. Modest and sustained weight loss has been shown to improve glycemic control
and reduce the need for glucose-lowering medications. Clinical benefits can be seen
with a minimum of 3–5% weight loss.
Assessment
Recommendations
8.1 Measure height and weight and calculate BMI at annual visits or more frequently.
E
8.2 Based on clinical considerations, such as the presence of comorbid heart failure
(HF) or significant unexplained weight gain or loss, weight may need to be monitored
and evaluated more frequently. B If deterioration of medical status is associated
with significant weight gain or loss, inpatient evaluation should be considered, specifically
focused on the association between medication use, food intake, and glycemic status.
E
8.3 For patients with a high level of weight-related distress, special accommodations
should be made to ensure privacy during weighing. E
Diet, Physical Activity, and Behavioral Therapy
Recommendations
8.4 Diet, physical activity, and behavioral therapy designed to achieve and maintain
≥5% weight loss is recommended for patients with type 2 diabetes who have overweight
or obesity and are ready to achieve weight loss. Greater benefits in control of diabetes
and CV factors may be gained from even greater weight loss. B
8.5 Such interventions should be high intensity (≥16 sessions in 6 months) and focus
on dietary changes, physical activity, and behavioral strategies to achieve a 500–750
kcal/day energy deficit. A
8.6 Individual’s motivation, life circumstances, and willingness to make lifestyle
changes to achieve weight loss should be assessed along with medical status when weight
loss interventions are undertaken. C
8.7 As all energy-deficit food intake will result in weight loss, eating plans should
be individualized to meet the patient’s protein, fat, and carbohydrate needs while
still promoting weight loss. A
8.8 Food availability should be queried, as well as other cultural circumstances that
could affect dietary patterns. C
8.9 For patients who achieve short-term weight-loss goals, long-term (≥1 year) weight
maintenance programs are recommended when available. Such programs should at minimum
provide monthly contact, as well as encourage ongoing monitoring of body weight (weekly
or more frequently) and other self-monitoring strategies, including participation
in high levels of physical activity (200–300 min/week). A
8.10 To achieve weight loss of >5%, short-term (3-month) interventions that use very
low-calorie diets (≤800 kcal/day) and meal replacements may be prescribed for carefully
selected patients by trained practitioners in medical care settings with close medical
monitoring. To maintain weight loss, such programs must incorporate long-term comprehensive
weight-maintenance counseling. B
Pharmacotherapy
Recommendations
8.11 When choosing glucose-lowering medications for patients with type 2 diabetes
and overweight or obesity, consider a medication’s effect on weight. B
8.12 Whenever possible, minimize medications for comorbid conditions that are associated
with weight gain. E
8.13 Weight-loss medications are effective as adjuncts to diet, physical activity,
and behavioral counseling for selected patients with type 2 diabetes and BMI ≥27 kg/m2.
Potential benefits must be weighed against potential risks of medications. A
8.14 If a patient’s response to weight-loss medications is <5% weight loss after 3
months or if there are significant safety or tolerability issues at any time, the
medication should be discontinued and alternative medications or treatment approaches
should be considered. A
The FDA has approved medications for both short- and long-term weight management along
with diet, exercise, and behavioral therapy. Nearly all of these FDA-approved medications
have been found to improve glycemic control in patients with type 2 diabetes and delay
progression to type 2 diabetes in patients at risk. Table 8.2 in the complete 2020
Standards of Care provides a list of FDA-approved medications for the treatment of
obesity, along with their advantages and disadvantages. The efficacy and safety of
these medications should be assessed at least monthly for the first 3 months.
Metabolic Surgery
Recommendations
8.15 Metabolic surgery should be recommended as an option to treat type 2 diabetes
in screened surgical candidates with BMI ≥40 kg/m2 (BMI ≥37.5 kg/m2 in Asian Americans)
and in adults with BMI 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in Asian Americans) who do
not achieve durable weight loss and improvement in comorbidities (including hyperglycemia)
with nonsurgical methods. A
8.16 Metabolic surgery may be considered as an option for adults with type 2 diabetes
and BMI 30.0–34.9 kg/m2 (27.5–32.4 kg/m2 in Asian Americans) who do not achieve durable
weight loss and improvement in comorbidities (including hyperglycemia) with tested
efficacious nonsurgical methods. A
8.17 Metabolic surgery should be performed in high-volume centers with multidisciplinary
teams knowledgeable about and experienced in the management of diabetes and gastrointestinal
surgery. E
8.18 Long-term lifestyle support and routine monitoring of micronutrient and nutritional
status must be provided to patients after surgery, according to guidelines for postoperative
management of metabolic surgery by national and international professional societies.
C
8.19 People being considered for metabolic surgery should be evaluated for comorbid
psychological conditions and social and situational circumstances that have the potential
to interfere with surgery outcomes. B
8.20 People who undergo metabolic surgery should routinely be evaluated to assess
the need for ongoing mental health services to help with the adjustment to medical
and psychosocial changes after surgery. C
9. PHARMACOLOGIC APPROACHES TO GLYCEMIC TREATMENT
Pharmacologic Therapy for Type 1 Diabetes
Recommendations
9.1 Most people with type 1 diabetes should be treated with MDI of prandial and basal
insulin or CSII. A
9.2 Most individuals with type 1 diabetes should use rapid-acting insulin analogs
to reduce hypoglycemia risk. A
9.3 Patients with type 1 diabetes should be trained to match prandial insulin doses
to carbohydrate intake, premeal blood glucose, and anticipated physical activity.
C
See “9. Pharmacologic Approaches to Glycemic Treatment” in the complete 2020 Standards
of Care for more detailed information on pharmacologic approaches to type 1 diabetes
management.
Pharmacologic Therapy for Type 2 Diabetes
Figure 9.1, Figure 9.2, and Table 9.1 provide details for informed decision-making
on pharmacologic agents for type 2 diabetes.
FIGURE 9.1
Glucose-lowering medication in type 2 diabetes: overall approach. For appropriate
context, see Figure 4.1. CREDENCE, Evaluation of the Effects of Canagliflozin on Renal
and Cardiovascular Outcomes in Participants With Diabetic Nephropathy. CVOTs, CV outcomes
trials; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, GLP-1 receptor agonist;
SGLT2i, SGLT2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione. Adapted from Davies
MJ, D'Alessio DA, Fradkin J, et al. Diabetes Care 2018;41:2669–2701 and Buse JB, Wexler
DJ, Tsapas A, et al. Diabetes Care 19 December 2019 [Epub ahead of print]. DOI: 10.2337/dci19-0066.
FIGURE 9.2
Intensifying to injectable therapies. FPG, fasting plasma glucose; FRC, fixed-ratio
combination; GLP-1 RA, GLP-1 receptor agonist; iDegLira, insulin degludec/liraglutide;
iGlarLixi, insulin glargine/lixisenatide; max, maximum; PPG, postprandial glucose;
Table 9.3 appears in the complete 2020 Standards of Care. Adapted from Davies MJ,
D'Alessio DA, Fradkin J, et al. Diabetes Care 2018;41:2669–2701.
TABLE 9.1
Drug-specific and patient factors to consider when selecting antihyperglycemic treatment
in adults with type 2 diabetes
*For agent-specific dosing recommendations, please refer to the manufacturers’ prescribing
information. †FDA-approved for CVD benefit. ‡FDA-approved for HF indication. §FDA-approved
for CKD indication. DPP-4, dipeptidyl peptidase 4; DKA, diabetic ketoacidosis; GLP-1
RAs, GLP-1 receptor agonists; NASH, nonalcoholic steatohepatitis; SQ, subcutaneous;
T2DM, type 2 diabetes.
Recommendations
9.4 Metformin is the preferred initial pharmacologic agent for the treatment of type
2 diabetes. A
9.5 Once initiated, metformin should be continued as long as it is tolerated and not
contraindicated; other agents, including insulin, should be added to metformin. A
9.6 Early combination therapy can be considered in some patients at treatment initiation
to extend the time to treatment failure. A
9.7 The early introduction of insulin should be considered if there is evidence of
ongoing catabolism (weight loss), if symptoms of hyperglycemia are present, or when
A1C levels (>10% [86 mmol/mol]) or blood glucose levels (≥300 mg/dL [16.7 mmol/L])
are very high. E
9.8 A patient-centered approach should be used to guide the choice of pharmacologic
agents. Considerations include CV comorbidities, hypoglycemia risk, impact on weight,
cost, risk for side effects, and patient preferences (Figure 9.1). E
9.9 Among patients with type 2 diabetes who have established ASCVD or indicators of
high-risk, established kidney disease, or HF, a sodium–glucose cotransporter 2 (SGLT2)
inhibitor or glucagon-like peptide 1 (GLP-1) receptor agonist with demonstrated CVD
benefit (Table 9.1) is recommended as part of the glucose-lowering regimen independent
of A1C and in consideration of patient-specific factors (Figure 9.1). A
9.10 In patients with type 2 diabetes who need greater glucose lowering than can be
obtained with oral agents, GLP-1 receptor agonists are preferred to insulin when possible.
B
9.11 Intensification of treatment for patients with type 2 diabetes not meeting treatment
goals should not be delayed. B
9.12 The medication regimen and medication-taking behavior should be reevaluated at
regular intervals (every 3–6 months) and adjusted as needed to incorporate specific
factors that impact choice of treatment (Figure 4.1 and Table 9.1). E
CV Outcomes Trials
See “10. CVD and Risk Management” below for details.
10. CVD AND RISK MANAGEMENT
This section has received endorsement from the American College of Cardiology.
ASCVD—defined as coronary heart disease, cerebrovascular disease, or peripheral arterial
disease (PAD) presumed to be of atherosclerotic origin—is the leading cause of morbidity
and mortality for individuals with diabetes. HF is another major cause of morbidity
and mortality from CVD. For prevention and management of both ASCVD and HF, CV risk
factors should be systematically assessed at least annually in all patients with diabetes.
These risk factors include obesity/overweight, hypertension, dyslipidemia, smoking,
a family history of premature coronary disease, chronic kidney disease (CKD), and
the presence of albuminuria.
The Risk Calculator
The American College of Cardiology/American Heart Association ASCVD risk calculator
(Risk Estimator Plus) is a useful tool to estimate 10-year ASCVD risk (http://tools.acc.org/ASCVD-Risk-Estimator-Plus).
This calculator includes diabetes as a risk factor because diabetes itself confers
increased risk for ASCVD. It should be acknowledged that this risk calculator does
not account for duration of diabetes or the presence of diabetes complications such
as albuminuria.
Hypertension/Blood Pressure Control
Screening and Diagnosis
Recommendations
10.1 Blood pressure should be measured at every routine clinical visit. Patients found
to have elevated blood pressure (≥140/90 mmHg) should have blood pressure confirmed
using multiple readings, including measurements on a separate day, to diagnose hypertension.
B
10.2 All hypertensive patients with diabetes should monitor their blood pressure at
home. B
Treatment Goals
Recommendations
10.3 For patients with diabetes and hypertension, blood pressure targets should be
individualized through a shared decision-making process that addresses CV risk, potential
adverse effects of antihypertensive medications, and patient preferences. C
10.4 For individuals with diabetes and hypertension at higher CV risk (existing ASCVD
or 10-year ASCVD risk ≥15%), a blood pressure target of <130/80 mmHg may be appropriate,
if it can be safely attained. C
10.5 For individuals with diabetes and hypertension at lower risk for CVD (10-year
ASCVD risk <15%), treat to a blood pressure target of <140/90 mmHg. A
10.6 In pregnant patients with diabetes and preexisting hypertension, a blood pressure
target of ≤135/85 mmHg is suggested in the interest of reducing the risk for accelerated
maternal hypertension A and minimizing impaired fetal growth. E
Individualization of Treatment Targets
Patients and clinicians should engage in a shared decision-making process to determine
individual blood pressure targets. Potential adverse effects of antihypertensive therapy
(e.g., hypotension, syncope, falls, acute kidney injury, and electrolyte abnormalities)
should also be taken into account. Patients with older age, CKD, and frailty have
been shown to be at higher risk of adverse effects of intensive blood pressure control.
Treatment Strategies
Figure 10.1 provides an algorithm for the treatment of confirmed hypertension in people
with diabetes.
FIGURE 10.1
Recommendations for the treatment of confirmed hypertension in people with diabetes.
*An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension for patients with
a UACR 30–299 mg/g Cr and strongly recommended for patients with a UACR ≥300 mg/g
Cr. **Thiazide-like diuretic; long-acting agents shown to reduce CV events, such as
chlorthalidone and indapamide, are preferred. ***Dihydropyridine CCB. BP, blood pressure.
Adapted from de Boer IH, Bangalore S, Benetos A, et al. Diabetes Care 2017;40:1273–1284.
Lifestyle Intervention
Recommendation
10.7 For patients with blood pressure >120/80 mmHg, lifestyle intervention consists
of weight loss if they have overweight or obesity, a Dietary Approaches to Stop Hypertension
(DASH)-style eating pattern including reducing sodium and increasing potassium intake,
moderation of alcohol intake, and increased physical activity. A
Pharmacologic Interventions
Recommendations
10.8 Patients with confirmed office-based blood pressure ≥140/90 mmHg should, in addition
to lifestyle therapy, have prompt initiation and timely titration of pharmacologic
therapy to achieve blood pressure goals. A
10.9 Patients with confirmed office-based blood pressure ≥160/100 mmHg should, in
addition to lifestyle therapy, have prompt initiation and timely titration of two
drugs or a single-pill combination of drugs demonstrated to reduce CV events in patients
with diabetes. A
10.10 Treatment for hypertension should include drug classes demonstrated to reduce
CV events in patients with diabetes (ACE inhibitors, angiotensin receptor blockers
[ARBs], thiazide-like diuretics, or dihydropyridine calcium channel blockers [CCBs]).
A
10.11 Multiple-drug therapy is generally required to achieve blood pressure targets.
However, combinations of ACE inhibitors and ARBs and combinations of ACE inhibitors
or ARBs with direct renin inhibitors should not be used. A
10.12 An ACE inhibitor or ARB, at the maximum tolerated dose indicated for blood pressure
treatment, is the recommended first-line treatment for hypertension in patients with
diabetes and urinary albumin-to-creatinine ratio (UACR) ≥300 mg/g creatinine (Cr)
A or 30–299 mg/g Cr. B If one class is not tolerated, the other should be substituted.
B
10.13 For patients treated with an ACE inhibitor, ARB, or diuretic, serum Cr/estimated
glomerular filtration rate (eGFR) and serum potassium levels should be monitored at
least annually. B
Resistant Hypertension
Recommendation
10.14 Patients with hypertension who are not meeting blood pressure targets on three
classes of antihypertensive medications (including a diuretic) should be considered
for mineralocorticoid receptor antagonist therapy. B
Prior to diagnosing resistant hypertension, a number of other conditions should be
excluded, including medication nonadherence, white coat hypertension, and secondary
hypertension. Mineralocorticoid receptor antagonists are effective for management
of resistant hypertension in patients with type 2 diabetes when added to existing
treatment with an ACE inhibitor or ARB, thiazide-like diuretic, or dihydropyridine
CCB.
Lipid Management
Lifestyle Intervention
Recommendations
10.15 Lifestyle modification focusing on weight loss (if indicated); application of
a Mediterranean-style or DASH eating pattern; reduction of saturated fat and trans
fat; increase of dietary n-3 fatty acids, viscous fiber, and plant stanols/sterols
intake; and increased physical activity should be recommended to improve the lipid
profile and reduce the risk of developing ASCVD in patients with diabetes. A
10.16 Intensify lifestyle therapy and optimize glycemic control for patients with
elevated triglyceride levels (≥150 mg/dL [1.7 mmol/L]) and/or low HDL cholesterol
(<40 mg/dL [1.0 mmol/L] for men, <50 mg/dL [1.3 mmol/L] for women). C
Ongoing Therapy and Monitoring With Lipid Panel
Recommendations
10.17 In adults not taking statins or other lipid-lowering therapy, it is reasonable
to obtain a lipid profile at the time of diabetes diagnosis, at an initial medical
evaluation, and every 5 years thereafter if under the age of 40 years, or more frequently
if indicated. E
10.18 Obtain a lipid profile at initiation of statins or other lipid-lowering therapy,
4–12 weeks after initiation or a change in dose, and annually thereafter as it may
help to monitor the response to therapy and inform medication adherence. E
Statin Treatment
Recommendations
10.19 For patients with diabetes aged 40–75 years without ASCVD, use moderate-intensity
statin therapy in addition to lifestyle therapy. A
10.20 For patients with diabetes aged 20–39 years with additional ASCVD risk factors,
it may be reasonable to initiate statin therapy in addition to lifestyle therapy.
C
10.21 In patients with diabetes at higher risk, especially those with multiple ASCVD
risk factors or aged 50–70 years, it is reasonable to use high-intensity statin therapy.
B
10.22 In adults with diabetes and 10-year ASCVD risk of 20% or higher, it may be reasonable
to add ezetimibe to maximally tolerated statin therapy to reduce LDL cholesterol levels
by 50% or more. C
Secondary Prevention
10.23 For patients of all ages with diabetes and ASCVD, high-intensity statin therapy
should be added to lifestyle therapy. A
10.24 For patients with diabetes and ASCVD considered very high risk using specific
criteria, if LDL cholesterol is ≥70 mg/dL on maximally tolerated statin dose, consider
adding additional LDL-lowering therapy (such as ezetimibe or PCSK9 inhibitor). A Ezetimibe
may be preferred due to lower cost.
10.25 For patients who do not tolerate the intended intensity, the maximally tolerated
statin dose should be used. E
10.26 In adults with diabetes aged >75 years already on statin therapy, it is reasonable
to continue statin treatment. B
10.27 In adults with diabetes aged >75 years, it may be reasonable to initiate statin
therapy after discussion of potential benefits and risks. C
10.28 Statin therapy is contraindicated in pregnancy. B
Treatment of Other Lipoprotein Fractions or Targets
Recommendations
10.29 For patients with fasting triglyceride levels ≥500 mg/dL, evaluate for secondary
causes of hypertriglyceridemia and consider medical therapy to reduce the risk of
pancreatitis. C
10.30 In adults with moderate hypertriglyceridemia (fasting or nonfasting triglycerides
175–499 mg/dL), clinicians should address and treat lifestyle factors (obesity and
metabolic syndrome), secondary factors (diabetes, chronic liver or kidney disease
and/or nephrotic syndrome, hypothyroidism), and medications that raise triglycerides.
C
10.31 In patients with ASCVD or other CV risk factors on a statin with controlled
LDL cholesterol but elevated triglycerides (135–499 mg/dL), the addition of icosapent
ethyl can be considered to reduce CV risk. A
Other Combination Therapy
Recommendations
10.32 Statin plus fibrate combination therapy has not been shown to improve ASCVD
outcomes and is generally not recommended. A
10.33 Statin plus niacin combination therapy has not been shown to provide additional
CV benefit above statin therapy alone, may increase the risk of stroke with additional
side effects, and is generally not recommended. A
Diabetes Risk With Statin Use
Several studies have reported a modestly increased risk of incident diabetes with
statin use, which may be limited to those with diabetes risk factors. A meta-analysis
of 13 randomized statin trials showed an odds ratio of 1.09 for a new diagnosis of
diabetes, so that (on average) treatment of 255 patients with statins for 4 years
resulted in one additional case of diabetes while simultaneously preventing 5.4 vascular
events among those 255 patients.
Lipid-Lowering Agents and Cognitive Function
A concern that statins or other lipid-lowering agents might cause cognitive dysfunction
or dementia is not currently supported by evidence and should not deter their use
in individuals with diabetes at high risk for ASCVD.
Antiplatelet Agents
Recommendations
10.34 Use aspirin therapy (75–162 mg/day) as a secondary prevention strategy in those
with diabetes and a history of ASCVD. A
10.35 For patients with ASCVD and documented aspirin allergy, clopidogrel (75 mg/day)
should be used. B
10.36 Dual antiplatelet therapy (with low-dose aspirin and a P2Y12 inhibitor) is reasonable
for a year after an acute coronary syndrome A and may have benefits beyond this period.
B
10.37 Aspirin therapy (75–162 mg/day) may be considered as a primary prevention strategy
in those with diabetes who are at increased CV risk, after a comprehensive discussion
with the patient on the benefits versus the comparable increased risk of bleeding.
A
Risk Reduction
Aspirin has been shown to be effective in reducing CV morbidity and mortality in high-risk
patients with previous myocardial infarction or stroke (secondary prevention) and
is strongly recommended. In primary prevention, however, among patients with no previous
CV events, its net benefit is more controversial. Recommendations for using aspirin
as primary prevention include both men and women aged ≥50 years with diabetes and
at least one additional major risk factor (family history of premature ASCVD, hypertension,
dyslipidemia, smoking, or CKD/albuminuria) who are not at increased risk of bleeding
(e.g., older age, anemia, renal disease). The main adverse effect is an increased
risk of gastrointestinal bleeding.
CVD
Recommendations
Screening
10.38 In asymptomatic patients, routine screening for coronary artery disease is not
recommended as it does not improve outcomes as long as ASCVD risk factors are treated.
A
10.39 Consider investigations for coronary artery disease in the presence of any of
the following: atypical cardiac symptoms (e.g., unexplained dyspnea, chest discomfort);
signs or symptoms of associated vascular disease including carotid bruits, transient
ischemic attack, stroke, claudication, or PAD; or electrocardiogram abnormalities
(e.g., Q waves). E
Treatment
10.40 In patients with known ASCVD, consider ACE inhibitor or ARB therapy to reduce
the risk of CV events. B
10.41 In patients with prior myocardial infarction, β-blockers should be continued
for at least 2 years after the event. B
10.42 In patients with type 2 diabetes with stable HF, metformin may be continued
for glucose lowering if eGFR remains >30 mL/min but should be avoided in unstable
or hospitalized patients with HF. B
10.43 Among patients with type 2 diabetes who have established ASCVD or established
kidney disease, an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated CVD
benefit is recommended as part of the glucose-lowering regimen. A
10.43a In patients with type 2 diabetes and established ASCVD, multiple ASCVD risk
factors, or DKD, an SGLT2 inhibitor with demonstrated CV benefit is recommended to
reduce the risk of major adverse CV events and HF hospitalization. A
10.43b In patients with type 2 diabetes and established ASCVD or multiple risk factors
for ASCVD, a GLP-1 receptor agonist with demonstrated CV benefit is recommended to
reduce the risk of major adverse CV events. A
10.43c In patients with type 2 diabetes and established HF, an SGLT2 inhibitor may
be considered to reduce risk of HF hospitalization. C
Numerous large, randomized controlled trials have reported statistically significant
reductions in CV events for three of the FDA-approved SGLT2 inhibitors (empagliflozin,
canagliflozin, and dapagliflozin) and four FDA-approved GLP-1 receptor agonists (liraglutide,
albiglutide [although that agent was removed from the market for business reasons],
semaglutide [lower risk of CV events in a moderate-sized clinical trial but one not
powered as a CV outcomes trial], and dulaglutide). SGLT2 inhibitors also appear to
reduce risk of HF hospitalization and progression of kidney disease in patients with
established ASCVD, multiple risk factors for ASCVD, or DKD.
11. MICROVASCULAR COMPLICATIONS AND FOOT CARE
CKD
Recommendations
Screening
11.1 At least once a year, assess urinary albumin (e.g., spot UACR) and eGFR in patients
with type 1 diabetes with duration of ≥5 years and in all patients with type 2 diabetes
regardless of treatment. B Patients with urinary albumin >30 mg/g Cr and/or an eGFR
<60 mL/min/1.73 m2 should be monitored twice annually to guide therapy. C
Treatment
11.2 Optimize glucose control to reduce the risk or slow the progression of CKD. A
11.3 For patients with type 2 diabetes and DKD, consider use of an SGLT2 inhibitor
in patients with an eGFR ≥30 mL/min/1.73 m2 and urinary albumin >30 mg/g Cr, particularly
in those with urinary albumin >300 mg/g Cr, to reduce risk of CKD progression, CV
events, or both. A In patients with CKD who are at increased risk for CV events, use
of a GLP-1 receptor agonist may reduce risk of progression of albuminuria, CV events,
or both (Table 9.1). C
11.4 Optimize blood pressure control to reduce the risk or slow the progression of
CKD. A
11.5 Do not discontinue renin-angiotensin system blockade for minor increases in serum
Cr (<30%) in the absence of volume depletion. B
11.6 For people with nondialysis-dependent CKD, dietary protein intake should be approximately
0.8 g/kg body weight per day (the recommended daily allowance). A For patients on
dialysis, higher levels of dietary protein intake should be considered, since malnutrition
is a major problem in some dialysis patients. B
11.7 In nonpregnant patients with diabetes and hypertension, either an ACE inhibitor
or an ARB is recommended for those with modestly elevated UACR (30–299 mg/g Cr) B
and is strongly recommended for those with UACR ≥300 mg/g Cr and/or eGFR <60 mL/min/1.73
m2. A
11.8 Periodically monitor serum Cr and potassium levels for the development of increased
Cr or changes in potassium when ACE inhibitors, ARBs, or diuretics are used. B
11.9 An ACE inhibitor or ARB is not recommended for the primary prevention of CKD
in patients with diabetes who have normal blood pressure, normal UACR (<30 mg/g Cr),
and normal eGFR. A
11.10 Patients should be referred for evaluation by a nephrologist if they have an
eGFR <30 mL/min/1.73 m2. A
11.11 Promptly refer to a physician experienced in the care of kidney disease for
uncertainty about the etiology of kidney disease, difficult management issues, and
rapidly progressing kidney disease. A
Epidemiology and Staging of CKD
CKD is characterized by persistent albuminuria, low eGFR, and other manifestations
of kidney damage (Figure 11.1). The degree of albuminuria is associated with CKD progression,
CVD, and mortality. CKD among people with diabetes markedly increases CVD risk and
health care costs.
FIGURE 11.1
Risk of CKD progression, frequency of visits, and referral to nephrology according
to GFR and albuminuria. The GFR and albuminuria grid depicts the risk of progression,
morbidity, and mortality by color, from best to worst (green, yellow, orange, red,
dark red). The numbers in the boxes are a guide to the frequency of visits (number
of times per year). Green can reflect CKD with normal eGFR and UACR only in the presence
of other markers of kidney damage, such as imaging showing polycystic kidney disease
or kidney biopsy abnormalities, with follow-up measurements annually; yellow requires
caution and measurements at least once per year; orange requires measurements twice
per year; red requires measurements three times per year; and dark red requires measurements
four times per year. These are general parameters only, based on expert opinion, and
underlying comorbid conditions and disease state as well as the likelihood of impacting
a change in management for any individual patient must be taken into account. “Refer”
indicates that nephrology services are recommended. *Referring clinicians may wish
to discuss with their nephrology service, depending on local arrangements regarding
treating or referring. Reprinted with permission from Vassalotti JA, Centor R, Turner
BJ, Greer RC, Choi M, Sequist TD; National Kidney Foundation Kidney Disease Outcomes
Quality Initiative. Am J Med 2016;129:153–162.e7.
Selection of Glucose-Lowering Medications for People With CKD
Metformin is contraindicated for use in patients with an eGFR <30 mL/min/1.73 m2.
Treatment with metformin should be reassessed for patients with an eGFR <45 mL/min/1.73
m2 and should be temporarily discontinued at the time of or before iodinated contrast
imaging procedures in patients with eGFR 30–60 mL/min/1.73 m2. SGLT2 inhibitors and
GLP-1 receptor agonists should be considered for patients with type 2 diabetes and
CKD who require another drug added to metformin to attain target A1C or cannot use
or tolerate metformin. Agents from these drug classes are suggested because they appear
to reduce risks of CKD progression, CVD events, and hypoglycemia. Several large clinical
trials have proven the effectiveness of both SGLT2 and GLP-1 receptor agonists in
reducing the progression of albuminuria and the risk of developing or worsening nephropathy.
A detailed summary of the clinical trials data can be found in “11. Microvascular
Complications and Foot Care” in the complete 2020 Standards of Care.
Two clinical trials studied the combinations of ACE inhibitors and ARBs and found
no benefits on CVD or CKD and a higher rate of adverse events (hyperkalemia and/or
acute kidney injury) with the combination. Therefore, the combined use of an ACE inhibitor
and an ARB should be avoided.
Diabetic Retinopathy
Recommendations
11.12 Optimize glycemic control to reduce the risk or slow the progression of diabetic
retinopathy. A
11.13 Optimize blood pressure and serum lipid control to reduce the risk or slow the
progression of diabetic retinopathy. A
Screening
11.14 Adults with type 1 diabetes should have an initial dilated and comprehensive
eye examination by an ophthalmologist or optometrist within 5 years after the onset
of diabetes. B
11.15 Patients with type 2 diabetes should have an initial dilated and comprehensive
eye examination by an ophthalmologist or optometrist at the time of the diabetes diagnosis.
B
11.16 If there is no evidence of retinopathy for one or more annual eye exams and
glycemia is well controlled, then screening every 1–2 years may be considered. If
any level of diabetic retinopathy is present, subsequent dilated retinal examinations
should be repeated at least annually by an ophthalmologist or optometrist. If retinopathy
is progressing or sight-threatening, then examinations will be required more frequently.
B
11.17 Programs that use retinal photography (with remote reading or use of a validated
assessment tool) to improve access to diabetic retinopathy screening can be appropriate
screening strategies for diabetic retinopathy. Such programs need to provide pathways
for timely referral for a comprehensive eye examination when indicated. B
11.18 Women with preexisting type 1 or type 2 diabetes who are planning pregnancy
or who are pregnant should be counseled on the risk of development and/or progression
of diabetic retinopathy. B
11.19 Eye examinations should occur before pregnancy or in the first trimester in
patients with preexisting type 1 or type 2 diabetes, and then patients should be monitored
every trimester and for 1 year postpartum as indicated by the degree of retinopathy.
B
Treatment
11.20 Promptly refer patients with any level of macular edema, severe nonproliferative
diabetic retinopathy (a precursor of proliferative diabetic retinopathy), or any proliferative
diabetic retinopathy to an ophthalmologist who is knowledgeable and experienced in
the management of diabetic retinopathy. A
11.21 The traditional standard treatment, panretinal laser photocoagulation therapy,
is indicated to reduce the risk of vision loss in patients with high-risk proliferative
diabetic retinopathy and, in some cases, severe nonproliferative diabetic retinopathy.
A
11.24 The presence of retinopathy is not a contraindication to aspirin therapy for
cardioprotection, as aspirin does not increase the risk of retinal hemorrhage. A
Neuropathy
Recommendations
Screening
11.25 All patients should be assessed for diabetic peripheral neuropathy starting
at diagnosis of type 2 diabetes and 5 years after the diagnosis of type 1 diabetes
and at least annually thereafter. B
11.26 Assessment for distal symmetric polyneuropathy should include a careful history
and assessment of either temperature or pinprick sensation (small fiber function)
and vibration sensation using a 128-Hz tuning fork (for large-fiber function). All
patients should have annual 10-g monofilament testing to identify feet at risk for
ulceration and amputation. B
11.27 Symptoms and signs of autonomic neuropathy should be assessed in patients with
microvascular complications. E
Treatment
11.28 Optimize glucose control to prevent or delay the development of neuropathy in
patients with type 1 diabetes A and to slow the progression of neuropathy in patients
with type 2 diabetes. B
11.29 Assess and treat patients to reduce pain related to diabetic peripheral neuropathy
B and symptoms of autonomic neuropathy and to improve quality of life. E
Neuropathic Pain
Pregabalin and duloxetine have received regulatory approval by the FDA in treating
diabetic neuropathic pain. Pregabalin is the most extensively studied drug for this
purpose, and duloxetine has also shown efficacy. Tapentadol, an opioid analgesic,
also has FDA approval for use in the treatment of diabetic neuropathic pain, but is
not recommended as a first- or second-line agent due to safety concerns surrounding
the risk of addiction.
Foot Care
Recommendations
11.31 Perform a comprehensive foot evaluation at least annually to identify risk factors
for ulcers and amputations. B
11.32 Patients with evidence of sensory loss or prior ulceration or amputation should
have their feet inspected at every visit. B
11.33 Obtain a prior history of ulceration, amputation, Charcot foot, angioplasty
or vascular surgery, cigarette smoking, retinopathy, and renal disease and assess
current symptoms of neuropathy (pain, burning, numbness) and vascular disease (leg
fatigue, claudication). B
11.34 The examination should include inspection of the skin, assessment of foot deformities,
neurological assessment (10-g monofilament testing with at least one other assessment:
pinprick, temperature, vibration), and vascular assessment including pulses in the
legs and feet. B
11.35 Patients with symptoms of claudication or decreased or absent pedal pulses should
be referred for ankle-brachial index and for further vascular assessment as appropriate.
C
11.36 A multidisciplinary approach is recommended for individuals with foot ulcers
and high-risk feet (e.g., dialysis patients and those with Charcot foot or prior ulcers
or amputation). B
11.37 Refer patients who smoke or who have histories of prior lower-extremity complications,
loss of protective sensation, structural abnormalities, or PAD to foot care specialists
for ongoing preventive care and lifelong surveillance. C
11.38 Provide general preventive foot self-care education to all patients with diabetes.
B
11.39 The use of specialized therapeutic footwear is recommended for high-risk patients
with diabetes including those with severe neuropathy, foot deformities, ulcers, callous
formation, poor peripheral circulation, or history of amputation. B
Foot ulcers and amputation, which are consequences of diabetic neuropathy and PAD,
are common and represent major causes of morbidity and mortality in people with diabetes.
Early recognition and treatment of patients with diabetes and feet at risk for ulcers
and amputations can delay or prevent adverse outcomes.
“11. Microvascular Complications and Foot Care” in the complete 2020 Standards of
Care provides further details on appropriate screening.
Treatment
People with neuropathy or evidence of increased plantar pressures (e.g., erythema,
warmth, or calluses) may be adequately managed with well-fitted walking shoes or athletic
shoes that cushion the feet and redistribute pressure. People with bony deformities
(e.g., hammertoes, prominent metatarsal heads, bunions) may need extra-wide or deep
shoes, and some will require custom-molded shoes. Use of custom therapeutic footwear
can help reduce the risk of future foot ulcers in high-risk patients.
12. OLDER ADULTS
Recommendations
12.1 Consider the assessment of medical, psychological, functional (self-management
abilities), and social geriatric domains in older adults to provide a framework to
determine targets and therapeutic approaches for diabetes management. B
12.2 Screen for geriatric syndromes (i.e., polypharmacy, cognitive impairment, depression,
urinary incontinence, falls, and persistent pain) in older adults as they may affect
diabetes self-management and diminish quality of life. B
Diabetes is an important health condition for the aging population. Approximately
one-quarter of people over the age of 65 years have diabetes and one-half of older
adults have prediabetes. Older adults with diabetes have higher rates of premature
death, functional disability, accelerated muscle loss, and coexisting illnesses, such
as hypertension, coronary heart disease, and stroke, than those without diabetes.
Screening for diabetes complications in older adults should be individualized and
periodically revisited, as the results of screening tests may impact targets and therapeutic
approaches. At the same time, older adults with diabetes also are at greater risk
than other older adults for several common geriatric syndromes, such as polypharmacy,
cognitive impairment, depression, urinary incontinence, injurious falls, and persistent
pain. If left unaddressed, these conditions may affect the diabetes self-management
abilities and quality of life of older adults with diabetes.
Neurocognitive Function
Recommendation
12.3 Screening for early detection of mild cognitive impairment or dementia should
be performed for adults 65 years of age or older at the initial visit and annually
as appropriate. B
Hypoglycemia
Recommendation
12.4 Hypoglycemia should be avoided in older adults with diabetes. It should be assessed
and managed by adjusting glycemic targets and pharmacologic regimens. B
Older adults are at higher risk of hypoglycemia for many reasons, including insulin
deficiency necessitating insulin therapy and progressive renal insufficiency. It is
important to prevent hypoglycemia to reduce the risk of cognitive decline and other
major adverse outcomes.
Treatment Goals
Recommendations
12.5 Older adults who are otherwise healthy with few coexisting chronic illnesses
and intact cognitive function and functional status should have lower glycemic goals
(such as A1C <7.5% [58 mmol/mol]), while those with multiple coexisting chronic illnesses,
cognitive impairment, or functional dependence should have less stringent glycemic
goals (such as A1C <8.0–8.5% [64–69 mmol/mol]). C
12.6 Glycemic goals for some older adults might reasonably be relaxed as part of individualized
care, but hyperglycemia leading to symptoms or risk of acute hyperglycemia complications
should be avoided in all patients. C
12.7 Screening for diabetes complications should be individualized in older adults.
Particular attention should be paid to complications that would lead to functional
impairment. C
12.8 Treatment of hypertension to individualized target levels is indicated in most
older adults. C
12.9 Treatment of other CV risk factors should be individualized in older adults considering
the time frame of benefit. Lipid-lowering therapy and aspirin therapy may benefit
those with life expectancies at least equal to the time frame of primary prevention
or secondary intervention trials. E
The care of older adults with diabetes is complicated by their clinical, cognitive,
and functional heterogeneity. Providers caring for older adults with diabetes must
take this heterogeneity into consideration when setting and prioritizing treatment
goals. For patients with complications and reduced functionality, it is reasonable
to set less intensive glycemic goals. Patients with good cognitive and physical function
may benefit from interventions and goals similar to those of younger adults.
Patients with type 1 diabetes are living longer, and the population of these patients
>65 years of age is growing. This population has unique challenges and requires distinct
treatment considerations. DSME and ongoing support are vital components of diabetes
care for older adults and their caregivers.
Older adults with diabetes are likely to benefit from control of other CV risk factors,
with treatment of hypertension to individualized target levels indicated in most.
There is less evidence for lipid-lowering and aspirin therapy, although the benefits
of these interventions are likely to apply to older adults whose life expectancies
equal or exceed the time frames of clinical prevention trials.
Lifestyle Management
Recommendation
12.10 Optimal nutrition and protein intake is recommended for older adults; regular
exercise, including aerobic activity and resistance training, should be encouraged
in all older adults who can safely engage in such activities. B
Pharmacologic Therapy
Recommendations
12.11 In older adults with type 2 diabetes at increased risk of hypoglycemia, medication
classes with low risk of hypoglycemia are preferred. B
12.12 Overtreatment of diabetes is common in older adults and should be avoided. B
12.13 Deintensification (or simplification) of complex regimens is recommended to
reduce the risk of hypoglycemia and polypharmacy, if it can be achieved within the
individualized A1C target. B
12.14 Consider costs of care and insurance coverage rules when developing treatment
plans in order to reduce risk of cost-related nonadherence. B
Special care is required in prescribing and monitoring pharmacologic therapies in
older adults. See Figure 9.1 for general recommendations regarding glucose-lowering
treatment for adults with type 2 diabetes and Table 9.1 for patient- and drug-specific
factors to consider when selecting glucose-lowering agents. Metformin is the first-line
agent for older adults with type 2 diabetes.
Tight glycemic control in older adults with multiple medical conditions is considered
overtreatment and is associated with an increased risk of hypoglycemia; unfortunately,
overtreatment is common in clinical practice. Deintensification of regimens in patients
taking noninsulin glucose-lowering medications can be achieved by either lowering
the dose or discontinuing some medications, so long as the individualized glycemic
target is maintained. Simplification of insulin regimens may also be appropriate.
The needs of older adults with diabetes and their caregivers should be evaluated to
construct a tailored care plan.
Treatment in Skilled Nursing Facilities and Nursing Homes
Recommendations
12.15 Consider diabetes education for the staff of long-term care (LTC) and rehabilitation
facilities to improve the management of older adults with diabetes. E
12.16 Patients with diabetes residing in long-term care facilities need careful assessment
to establish individualized glycemic goals and to make appropriate choices of glucose-lowering
agents based on their clinical and functional status. E
Management of diabetes is unique in the LTC setting. Practical guidance is needed
for medical providers as well as LTC staff and caregivers. Treatments for each patient
should be individualized. Special management considerations include the need to avoid
both hypoglycemia and the complications of hyperglycemia. The ADA position statement
“Management of Diabetes in Long-term Care and Skilled Nursing Facilities” provide
more information on this topic.
End-of-Life Care
Recommendations
12.17 When palliative care is needed in older adults with diabetes, providers should
initiate conversations regarding the goals and intensity of care. Strict glucose and
blood pressure control may not be necessary E, and reduction of therapy may be appropriate.
Similarly, the intensity of lipid management can be relaxed, and withdrawal of lipid-lowering
therapy may be appropriate. A
Overall, palliative medicine promotes comfort, symptom control and prevention (pain,
hypoglycemia, hyperglycemia, and dehydration), and preservation of dignity and quality
of life in patients with limited life expectancy. Different patient categories have
been proposed for diabetes management in those with advanced disease. These include
stable patients, patients with organ failure, and dying patients.
13. CHILDREN AND ADOLESCENTS
The management of diabetes in children and adolescents cannot simply be derived from
care routinely provided to adults with diabetes. The epidemiology, pathophysiology,
developmental considerations, and response to therapy in pediatric-onset diabetes
are different from adult diabetes.
Type 1 Diabetes
Type 1 diabetes is the most common form of diabetes in youth. A multidisciplinary
team of specialists trained in pediatric diabetes management and sensitive to the
challenges of children and adolescents with type 1 diabetes and their families should
provide care for this population.
See “13. Children and Adolescents” in the complete 2020 Standards of Care for specific
recommendations. The ADA position statements “Type 1 Diabetes in Children and Adolescents”
and “Evaluation and Management of Youth-Onset Type 2 Diabetes” offer additional information.
Type 2 Diabetes
Management
Recommendations
Glycemic Targets
13.59 A reasonable A1C target for most children and adolescents with type 2 diabetes
treated with oral agents alone is <7% (53 mmol/mol). More stringent A1C targets (such
as <6.5% [48 mmol/mol]) may be appropriate for selected individual patients if they
can be achieved without significant hypoglycemia or other adverse effects of treatment.
Appropriate patients might include those with short duration of diabetes and lesser
degrees of β-cell dysfunction and patients treated with lifestyle or metformin only
who achieve significant weight improvement. E
Pharmacologic Management
13.60 Less-stringent A1C goals (such as 7.5% [58 mmol/mol]) may be appropriate if
there is increased risk of hypoglycemia. E
13.62 Initiate pharmacologic therapy, in addition to lifestyle therapy, at diagnosis
of type 2 diabetes. A
13.63 In incidentally diagnosed or metabolically stable patients (A1C <8.5% [69 mmol/mol]
and asymptomatic), metformin is the initial pharmacologic treatment of choice if renal
function is normal. A
13.64 Youth with marked hyperglycemia (blood glucose ≥250 mg/dL [13.9 mmol/L], A1C
≥8.5% [69 mmol/mol]) without acidosis at diagnosis who are symptomatic with polyuria,
polydipsia, nocturia, and/or weight loss should be treated initially with basal insulin
while metformin is initiated and titrated. B
13.67 If glycemic targets are no longer met with metformin (with or without basal
insulin), liraglutide (a GLP-1 receptor agonist) therapy should be considered in children
10 years of age or older if they have no past medical history or family history of
medullary thyroid carcinoma or multiple endocrine neoplasia type 2. A
13.70 Use of medications not approved by the FDA for youth with type 2 diabetes is
not recommended outside of research trials. B
Transition From Pediatric to Adult Care
Recommendation
13.107 Pediatric diabetes providers should begin to prepare youth for transition to
adult health care in early adolescence and, at the latest, at least 1 year before
the transition. E
“13. Children and Adolescents” in the complete 2020 Standards of Care describes the
comprehensive treatment of children with type 2 diabetes.
14. MANAGEMENT OF DIABETES IN PREGNANCY
The prevalence of diabetes in pregnancy is increasing in the U.S. along with the epidemic
in obesity seen worldwide. Type 1 and type 2 diabetes are increasing in women of reproductive
age, and there also has been a dramatic increase in rates of GDM. Diabetes confers
an increase maternal and fetal risk. Specific risks of diabetes in pregnancy include
spontaneous abortion, fetal anomalies, preeclampsia, fetal demise, macrosomia, neonatal
hypoglycemia, hyperbilirubinemia, and neonatal respiratory distress syndrome, among
others. In addition, diabetes in pregnancy may increase the risk of obesity, hypertension,
and type 2 diabetes in offspring later in life.
Preconception Counseling
Recommendations
14.1 Starting at puberty and continuing in all women with diabetes and reproductive
potential, preconception counseling should be incorporated into routine diabetes care.
A
14.2 Family planning should be discussed, and effective contraception (with consideration
of long-acting, reversible contraception) should be prescribed and used until a woman’s
treatment regimen and A1C are optimized for pregnancy. A
14.3 Preconception counseling should address the importance of achieving glucose levels
as close to normal as is safely possible, ideally A1C <6.5% (48 mmol/mol), to reduce
the risk of congenital anomalies, preeclampsia, macrosomia, and other complications.
B
Preconception Care
Recommendations
14.4 Women with preexisting diabetes who are planning a pregnancy should ideally be
managed beginning in preconception in a multidisciplinary clinic including an endocrinologist,
maternal-fetal medicine specialist, dietitian, and diabetes educator, when available.
B
14.5 In addition to focused attention on achieving glycemic targets A, standard preconception
care should be augmented with extra focus on nutrition, diabetes education, and screening
for diabetes comorbidities and complications. E
14.6 Women with preexisting type 1 or type 2 diabetes who are planning pregnancy or
who have become pregnant should be counseled on the risk of development and/or progression
of diabetic retinopathy. Dilated eye examinations should occur ideally before pregnancy
or in the first trimester, and then patients should be monitored every trimester and
for 1 year postpartum as indicated by the degree of retinopathy and as recommended
by the eye care provider. B
Table 14.1 in the complete 2020 Standards of Care provides details on preconception
care. Diabetes-specific testing should be performed such as A1C, Cr, and UACR. “14.
Management of Diabetes in Pregnancy” in the complete 2020 Standards of Care provides
details on the management of preexisting diabetes in pregnancy.
Management of GDM
Recommendations
14.13 Lifestyle behavior change is an essential component of management of GDM and
may suffice for the treatment of many women. Insulin should be added if needed to
achieve glycemic targets. A
14.14 Insulin is the preferred medication for treating hyperglycemia in GDM. Metformin
and glyburide should not be used as first-line agents, as both cross the placenta
to the fetus. A Other oral and noninsulin injectable glucose-lowering medications
lack long-term safety data.
14.15 Metformin, when used to treat polycystic ovary syndrome and induce ovulation,
should be discontinued by the end of the first trimester. A
Studies have shown that at least 70–85% of women with GDM can control it with lifestyle
modification alone. The Dietary Reference Intake for all pregnant women recommends
a minimum of 175 g carbohydrate, a minimum of 71 g protein, and 28 g fiber. The diet
should not be high in saturated fat.
Pregnancy and Drug Considerations
Recommendations
14.19 In pregnant patients with diabetes and hypertension or significant proteinuria,
a consistent blood pressure >135/85 mmHg should be treated in the interest of optimizing
long-term maternal health. Blood pressure targets should range no lower than 120/80
mmHg, as lower blood pressure targets may impair fetal growth. C
14.20 Potentially harmful medications in pregnancy (i.e., ACE inhibitors, ARBs, statins)
should be stopped at conception and avoided in sexually active women of childbearing
age who are not using reliable contraception. B
Postpartum Care
Recommendations
14.21 Insulin resistance decreases dramatically immediately postpartum, and insulin
requirements need to be evaluated and adjusted as they are often roughly half the
prepregnancy requirements for the initial few days postpartum. C
14.22 A contraceptive plan should be discussed and implemented with all women with
diabetes of reproductive potential. C
14.23 Screen women with a recent history of GDM at 4–12 weeks postpartum, using the
75-g oral glucose tolerance test and clinically appropriate nonpregnancy diagnostic
criteria. B
14.24 Women with a history of GDM found to have prediabetes should receive intensive
lifestyle interventions and/or metformin to prevent diabetes. A
14.25 Women with a history of GDM should have lifelong screening for the development
of type 2 diabetes or prediabetes at least every 3 years. B
14.26 Women with a history of GDM should seek preconception screening for diabetes
and preconception care to identify and treat hyperglycemia and prevent congenital
malformations. E
14.27 Postpartum care should include psychosocial assessment and support for self-care.
E
15. DIABETES CARE IN THE HOSPITAL
Among hospitalized patients, both hyperglycemia and hypoglycemia are associated with
adverse outcomes, including death. Therefore, careful management of inpatients with
diabetes has direct and immediate benefits. When caring for hospitalized patients
with diabetes, consult with a specialized diabetes or glucose management team when
possible.
Hospital Care Delivery Standards
Recommendations
15.1 Perform an A1C on all patients with diabetes or hyperglycemia (blood glucose
>140 mg/dL [7.8 mmol/L]) admitted to the hospital if not performed in the prior 3
months. B
15.2 Insulin should be administered using validated written or computerized protocols
that allow for predefined adjustments in the insulin dosage based on glycemic fluctuations.
C
Considerations on Admission
Initial orders should state the type of diabetes. Because inpatient treatment and
discharge planning are more effective if based on preadmission glycemia, an A1C should
be measured on all patients with diabetes or hyperglycemia.
Glycemic Targets in Hospitalized Patients
Recommendations
15.4 Insulin therapy should be initiated for treatment of persistent hyperglycemia
starting at a threshold ≥ 180 mg/dL (10.0 mmol/L). Once insulin therapy is started,
a target glucose range of 140–180 mg/dL (7.8–10.0 mmol/L) is recommended for the majority
of critically ill patients and noncritically ill patients. A
15.5 More stringent goals, such as 110–140 mg/dL (6.1–7.8 mmol/L), may be appropriate
for selected patients if they can be achieved without significant hypoglycemia. C
Hyperglycemia in hospitalized patients is defined as blood glucose levels >140 mg/dL
(7.8 mmol/L). An admission A1C value ≥6.5% (48 mmol/mol) suggests that diabetes preceded
hospitalization. Hypoglycemia in the hospital is classified the same as in any setting.
(See “6. Glycemic Targets” above.)
Bedside Blood Glucose Monitoring
In patients who are eating, glucose monitoring should be performed before meals; in
those not eating, glucose monitoring is advised every 4–6 h. Testing every 30 min
to every 2 h is required for intravenous insulin infusion.
Several inpatient studies have shown that CGM use did not improve glucose control
but detected a greater number of hypoglycemic events than point-of-care glucose testing.
However, there are insufficient data on clinical outcomes, safety, and cost-effectiveness
to recommend using CGM in hospitalized patients.
Glucose-Lowering Treatment in Hospitalized Patients
Recommendations
15.6 Basal insulin or a basal plus bolus correction insulin regimen is the preferred
treatment for noncritically ill hospitalized patients with poor oral intake or those
who are taking nothing by mouth. A An insulin regimen with basal, prandial, and correction
components is the preferred treatment for noncritically ill hospitalized patients
with good nutritional intake. A
15.7 Use of only a sliding scale insulin regimen in the inpatient hospital setting
is strongly discouraged. A
In most instances in the hospital setting, insulin is the preferred treatment for
glycemic control. In certain circumstances, it may be appropriate to continue home
regimens including oral glucose-lowering medications. If oral medications are held
in the hospital, there should be a protocol for resuming them 1–2 days before discharge.
Insulin Therapy
In the critical care setting, continuous intravenous insulin infusion is the best
method for achieving glycemic targets. Outside of critical care units, scheduled insulin
regimens as described above are recommended.
For patients who are eating, insulin injections should align with meals. In such instances,
point-of-care glucose testing should be performed immediately before meals. An insulin
regimen with basal and correction components is necessary for all hospitalized patients
with type 1 diabetes, with the addition of prandial insulin if patients are eating.
A transition protocol from insulin infusion to subcutaneous insulin is recommended.
Noninsulin Therapies
The safety and efficacy of noninsulin glucose-lowering therapies in the hospital setting
is an area of active research. See “15. Diabetes Care in the Hospital” in the complete
2020 Standards of Care for a comprehensive review of the inpatient use of these medications.
Hypoglycemia
Recommendations
15.8 A hypoglycemia management protocol should be adopted and implemented by each
hospital or hospital system. A plan for preventing and treating hypoglycemia should
be established for each patient. Episodes of hypoglycemia in the hospital should be
documented in the medical record and tracked. E
15.9 The treatment regimen should be reviewed and changed as necessary to prevent
further hypoglycemia when a blood glucose value of <70 mg/dL (3.9 mmol/L) is documented.
C
Patients with or without diabetes may experience hypoglycemia in the hospital setting.
While hypoglycemia is associated with increased mortality, it may be a marker of underlying
disease rather than the cause of fatality. Recently, several groups have developed
algorithms to predict episodes of hypoglycemia among inpatients. Models such as these
are potentially important and, once validated for general use, could provide a valuable
tool to reduce rates of hypoglycemia in hospitalized patients.
MNT in the Hospital
The goals of MNT in the hospital are to provide adequate calories to meet metabolic
demands, optimize glycemic control, and address personal food preferences, and facilitate
creation of a discharge plan. The ADA does not endorse any single meal plan. When
nutritional issues in the hospital are complex, the involvement of an RD/RDN can contribute
to patient care.
Self-Management in the Hospital
Diabetes self-management in the hospital may be appropriate for selected patients.
Sufficient cognitive and physical skills, adequate oral intake, proficiency in carbohydrate
estimation, and knowledge of sick-day management are some of the requirements. Self-administered
insulin with a stable MDI regimen or insulin pump therapy may be considered. A protocol
should exist for these situations.
Standards for Special Situations
See “15. Diabetes Care in the Hospital” in the complete 2020 Standards of Care for
guidance on enteral/parenteral feedings, glucocorticoid therapy, perioperative care,
and diabetic ketoacidosis and hyperosmolar hyperglycemic state.
Transition From the Acute Care Setting
Recommendation
15.10 There should be a structured discharge plan tailored to the individual patient
with diabetes. B
Transition from the acute care setting presents risk for all patients. A structured
discharge plan may reduce length of hospital stay and readmission rates and increase
patient satisfaction.
Medication Reconciliation
The patient’s medications must be cross-checked to ensure that no chronic medications
were stopped and to ensure the safety of new prescriptions.
Prescriptions for new or changed medication should be filled and reviewed with the
patient and family at or before discharge.
Discharge planning should begin at admission and be updated as patient needs change.
An outpatient follow-up visit 1 month after discharge is recommended. An earlier appointment
(in 1–2 weeks) is preferred, and frequent contact may be needed.
16. DIABETES ADVOCACY
For a list of ADA advocacy position statements, including “Diabetes and Driving” and
“Diabetes and Employment,” see “16. Diabetes Advocacy” in the complete 2020 Standards
of Care.